Skip to Content

HyQ Approval Status

HyQ (immune globulin and recombinant human hyaluronidase) is an investigational combination immunoglobulin product intended for the treatment of patients with primary immunodeficiencies.

In August 2012, Baxter International Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for HyQ had not been approved.

Development Status and FDA Approval Process for HyQ

Aug 20, 2012Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
Aug  2, 2012Baxter Confirms Receipt of Complete Response Letter on HyQ

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.